1952-LB: Impact of Automated Insulin Delivery Systems by Baseline HbA1c in Emerging Adults with Type 1 Diabetes

Introduction 7%, 7-9% and 9%). Results:HbA1c values (N=3137) were collected from 613 emerging adults with T1D (mean age 21.1±4.2 years, diabetes duration 10.8±6.0 years, male 44.5%, non-Hispanic White 76.8%). Mean HbA1c changed from 11.2% to 9.2% (baseline and 24 months) for HbA1c 9% (N=190); 8.3% to 7.9% for HbA1c 7-9% (N=314); and 6.5% to 6.8% for HbA1c 7% (N=109) (all p0.001). The percent with HbA1c 7% improved from 17.9% at baseline to 32.2% and 34.2% (3 and 24 months). Conclusion:AID initiation is associated with sustained improvements for those not initially meeting glycemic targets, particularly those with the highest HbA1cs. As most remained above target, additional strategies for improvement are required. Disclosure L.A. Waterman: None. G.T. Alonso: Advisory Panel; MannKind Corporation. C. Sakamoto: None. L. Pyle: None. G.P. Forlenza: Research Support; Abbott, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Medtronic. Advisory Panel; Medtronic. Research Support; Tandem Diabetes Care, Inc. Consultant; Tandem Diabetes Care, Inc. V.N. Shah: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi, Medscape. Consultant; embecta, Tandem Diabetes Care, Inc. E.C. Cobry: Advisory Panel; Dexcom, Inc. Other Relationship; Dexcom, Inc. Funding National Institutes of Health (5T32DK063687)